![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_1EN-1.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_2EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_3EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_4EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_5EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_6EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_7EN.jpg)
![](http://scienceupfirst.com/wp-content/uploads/sites/4/2024/02/NACI_Update_Fall2023_8EN.jpg)
The National Advisory Committee on Immunization (NACI) has updated its COVID-19 vaccine guidelines.
Their decision reflects the current COVID-19 situation in Canada (1,10,11,12):
- COVID-19 activity levels are overall moderate or low.
- Death numbers remain low, but have been increasing since July.
- The total number of hospital beds occupied due to COVID-19 is increasing (i.e. over 3,900 beds as of Oct. 24), with ICU beds mainly being occupied by individuals 80 years and older.
- Omicron’s XBB sub-lineage represents 94% of all variants currently circulating in Canada – EG.5 and its sub-lineages being the most abundant.
- A significant number of people living in Canada have developed immunity through prior infection, being lowest in those under 2 years old – older population seems to have higher immunity from vaccination alone.
We know these guidelines can be difficult to navigate sometimes. Don’t hesitate to ask us if you are not sure about something.
Share our original Tweet!
NACI updated their COVID-19 vaccine guidelines last month.
We know COVID-19 guidelines can be difficult to navigate, so we summarized them here https://t.co/aiJqycIQlc
Let us know if you have any questions!#ScienceUpFirst
— ScienceUpFirst | LaScienced’Abord (@ScienceUpFirst) November 10, 2023
View our original Instagram Post!
View this post on Instagram
- Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19 | FR : Mise à jour des directives sur l’utilisation des vaccins contre la COVID-19 chez les personnes qui n’ont pas été vaccinées auparavant contre la COVID-19
- Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023 | FR : Addenda aux directives sur l’utilisation des vaccins contre la COVID–19 à l’automne
- Moderna Spikevax COVID-19 vaccine | FR : Vaccin Spikevax de Moderna contre la COVID-19
- Product Monograph Including Patient Medication Information Spikevax® XBB.1.5 | FR : Monographie de produit incluant les renseignements sur le médicament pour le patient Le vaccin Spikevax® XBB.1.5
- Product Monograph Including Patient Medication Information Comirnaty®Omicron XBB.1.5 | FR : Monographie avec renseignements destinés aux patients Comirnaty®Omicron XBB.1.5
- Pfizer-BioNTech Comirnaty COVID-19 vaccine | FR : Vaccin Comirnaty de Pfizer-BioNTech contre la COVID-19
- COVID-19 vaccines: Canadian Immunization Guide | FR : Vaccins contre la COVID-19 : Guide canadien d’immunisation
- Influenza vaccines: Canadian Immunization Guide | FR : Vaccins antigrippaux : Guide canadien d’immunisation
- Guidance on the use of COVID-19 vaccines in the fall: NACI | FR : Directives sur l’utilisation des vaccins contre la COVID-19 à l’automne 2023
- COVID-19 epidemiology update: Summary | FR : Mise à jour sur l’épidémiologie de la COVID-19 : Résumé
- COVID-19 epidemiology update: Current situation | FR : Mise à jour sur l’épidémiologie de la COVID-19
- COVID-19 epidemiology update: Testing and variants | FR : Mise à jour sur l’épidémiologie de la COVID-19 : Dépistage et variants